ArticleCureus2025
Determining the Efficacy of Octreotide on Lymphorrhea Formation in Patients With Early Breast Carcinoma After Modified Radical Mastectomy: A Randomized Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative lymphorrhea and seroma formation are frequent complications after modified radical mastectomy (MRM) that can prolong recovery. Octreotide, a somatostatin analog with broad anti-secretory effects, has shown promise in reducing lymphatic drainage in various surgical settings. We conducted a randomized trial to evaluate the efficacy of octreotide in reducing lymphorrhea and seroma formation in patients with early breast cancer (stages I, IIA, and IIB) undergoing MRM.
methodsEighty patients with early breast carcinoma (stages I, IIA, and IIB) scheduled for MRM were randomly assigned to two groups (1:1 ratio). The octreotide group (n = 40) received injection octreotide subcutaneously 100 μg three times daily for five days and standard care postoperatively, while the control group received standard care without octreotide. Primary outcomes were the total volume of lymphorrhea drained until drain removal and the duration of drainage. Secondary outcomes included the incidence of postoperative seroma after drain removal, wound infection, flap necrosis, and length of hospital stay. Statistical analysis was performed using chi-square tests for categorical variables (α = 0.05) and t-tests for continuous variables.
resultsOctreotide significantly reduced the total lymphorrhea drainage volume (227.8 ± 181.4 ml; median 172.5, IQR 78.8-365.0) compared to the control group (364.1 ± 221.0 ml; median 352.5, IQR 198.8-562.5; U = 1081.5,
conclusionAdjuvant octreotide significantly reduced the volume of lymphorrhea following MRM, with quicker drain removal indicating its potential to decrease drainage output. Although the octreotide group showed a trend towards lower seroma incidence, the relationship was not statistically significant in our sample. Octreotide was well tolerated with no significant side effects. These findings suggest octreotide can be a safe adjunct to standard surgical care to reduce lymphatic drainage after MRM. Larger studies may further clarify its impact on seroma formation and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.